Cancer Stem Cell Targeting Peptide Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to specifically target cancer stem cells, which are resistant to chemotherapy, radiotherapy, and immune surveillance, and are a major cause of cancer relapse.
Innovation Solution
Development of synthetic peptides with specific amino acid sequences that selectively bind to cancer stem cells, allowing for targeted delivery of therapeutic agents and imaging contrast agents, and a method using a phage expression system to screen peptides that specifically target cancer stem cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and radiotherapy are used, then cancer treatment is provided, but cancer stem cells are not targeted and resistance develops leading to relapse
Solution Approach 1:
The patent applies local quality by designing peptides with specific amino acid sequences that are tailored to recognize and bind to unique surface markers on cancer stem cells. This localized specificity ensures that the therapeutic agent is delivered precisely to CSCs rather than affecting all cancer cells uniformly, thereby overcoming the resistance mechanism of CSCs to conventional therapies.
Solution Approach 2:
The patent introduces synthetic peptides as intermediary molecules that mediate between the therapeutic agent and cancer stem cells. These peptides act as targeting vectors that carry the therapeutic payload specifically to CSCs, enabling precise delivery while avoiding the resistance that plagues direct conventional therapy approaches.
2Manufacturing precision
If synthetic peptides are designed to specifically target cancer stem cells, then selective binding to CSCs is achieved, but development complexity increases
Solution Approach 1:
The patent employs phage display technology to perform preliminary screening and selection of peptides with CSC-targeting capability before final therapeutic development. This preliminary action allows researchers to identify and isolate high-affinity binding peptides from large libraries, significantly reducing the complexity of subsequent development steps by pre-selecting the most effective candidates.
Solution Approach 2:
The patent uses phage display to create copies of peptide sequences that can be rapidly screened and evaluated. By generating and testing numerous peptide variants in the phage system, researchers can identify optimal sequences without directly synthesizing and testing each variant in the final therapeutic context, thereby reducing overall development complexity.
3Measurement precision
If peptide libraries are screened using phage expression system, then specific CSC-targeting peptides are identified, but screening time and resource requirements increase
Solution Approach 1:
The patent segments the screening process into distinct phases: initial phage display screening to identify potential binders, followed by affinity maturation rounds to improve specificity, and final validation against CSCs. This segmentation allows each phase to be optimized independently, improving overall screening accuracy while managing time requirements through systematic progression.
Solution Approach 2:
The patent implements continuous screening cycles where phage-displayed peptides are repeatedly exposed to CSCs, with binding events continuously selected and amplified. This continuous useful action allows for progressive enrichment of high-affinity binders over multiple rounds, improving measurement precision while efficiently utilizing screening resources through uninterrupted selection pressure.
Data Source
AI summary
A synthetic peptide that targets cancer stem cells is provided. The peptide consists of the amino acid sequence of anyone of SEQ ID NO: 1 to SEQ ID NO: 15. Also provided is a composition comprising said synthetic peptide with a therapeutic agent fused thereto, and a pharmaceutically acceptable carrier or diluent. Further provided is a method of screening a peptide specifically targeting to a cancer stem cell. The method comprises the steps of establishing an oligopeptide library by using a phage expression system, contacting the library with a culture of bulk tumor cells of a cancer cell line, contacting the phages which do not bind to the bulk tumor cells with a culture of cancer stem cells of said cancer cell line, and screening a peptide specifically targeting to a cancer stem cell from the phages which bind to the cancer stem cells.